Status:
UNKNOWN
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Lead Sponsor:
Attikon Hospital
Conditions:
Severe Eosinophilic Asthma
Eligibility:
All Genders
18+ years
Brief Summary
A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient ch...
Eligibility Criteria
Inclusion
- Patients with uncontrolled severe eosinophilic asthma placed under treatment with mepolizumab, i.e. in patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants
Exclusion
- Patient refusal to participate in the study
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04084613
Start Date
January 1 2017
End Date
December 31 2020
Last Update
September 12 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.